# DLX2

## Overview
DLX2, or distal-less homeobox 2, is a gene that encodes a transcription factor belonging to the homeobox family, which is characterized by a conserved DNA-binding domain known as the homeodomain. This transcription factor plays a pivotal role in the regulation of gene expression during embryonic development and tissue differentiation. The DLX2 protein is involved in the morphogenesis of craniofacial structures, the development of the forebrain, and the formation of sensory organs, among other functions (Tan2021DLX). It interacts with various proteins and noncoding RNAs to modulate transcriptional activity, influencing pathways critical for cellular differentiation and development (Diamond2006Functional; Feng2006The). Alterations in DLX2 expression have been linked to several clinical conditions, including autism spectrum disorders and cancer, where it can affect cellular processes such as senescence and metastasis (Liu2008The; Tan2021DLX).

## Structure
DLX2 (distal-less homeobox 2) is a transcription factor characterized by the presence of a homeobox domain, which is a crucial DNA-binding motif involved in its function. The primary structure of DLX2 consists of specific amino acid sequences that form the basis for its functional properties. In terms of secondary structure, DLX2 includes elements such as alpha helices and beta sheets, which contribute to its stability and interaction with DNA.

The tertiary structure of DLX2 refers to its overall three-dimensional shape, which is essential for its interaction with other molecules and its role in transcriptional regulation. Although specific details about the quaternary structure of DLX2 are not provided, transcription factors like DLX2 often function as part of larger protein complexes, suggesting potential interactions with other protein subunits.

Post-translational modifications, such as phosphorylation, play a significant role in regulating the activity of DLX2. These modifications can alter the protein's function and its ability to bind DNA, thereby influencing gene expression during embryonic development. Additionally, splice variants of DLX2 may exist, potentially leading to differences in its functional properties and regulatory roles.

## Function
DLX2 is a transcription factor that plays a significant role in the development and differentiation of various tissues in healthy human cells. It is part of the homeobox family of genes, which are crucial for embryonic and postnatal development. DLX2 is involved in the morphogenesis of craniofacial structures, branchial arches, forebrain, and sensory organs (Tan2021DLX). In the context of chondrocyte differentiation, DLX2 is a downstream target of the BMP2 signaling pathway and is necessary for the expression of Col2alpha1 through a chondrocyte-specific enhancer. Overexpression of DLX2 leads to the accumulation of Aggrecan and type II collagen, major components of the cartilage matrix, by reducing the expression of the protease MMP13, which is involved in extracellular matrix degradation (Levi2022DLX).

DLX2 is also expressed in the developing forebrain and is essential for the formation of the retina. The absence of DLX2 results in the apoptosis of retinal ganglion cells and a diminished ganglion cell layer, leading to non-viability in newborn mice (Tan2021DLX). Additionally, DLX2 is involved in the development of the forebrain and regulates the expression of the DLX5/6 bigene (Tan2021DLX).

## Clinical Significance
Mutations and altered expression of the DLX2 gene have been implicated in various diseases and conditions. In the context of autism spectrum disorders (ASDs), DLX2 is associated with the development of GABAergic cortical interneurons, which are crucial for maintaining the balance between excitation and inhibition in the brain. An imbalance in this ratio has been suggested as a possible cause of autism. Studies have found significant associations between certain single nucleotide polymorphisms (SNPs) in DLX2 and increased susceptibility to ASDs, particularly in families with multiple affected individuals (Liu2008The).

In cancer, DLX2 plays a role in bypassing cellular senescence and promoting tumor progression. It can prolong the replicative lifespan of cells by weakening ATM/p53 signaling, which is crucial for inducing senescence. DLX2 overexpression is mutually exclusive with p53 defects in cancer patients, suggesting a unique pathway for tumorigenesis. It also promotes tumor invasion and metastasis by inducing SNAIL expression, a key factor in epithelial to mesenchymal transition (EMT) (Tan2021DLX). In breast cancer, DLX2 expression is associated with a less aggressive tumor phenotype, while its absence correlates with increased metastatic potential (Morini2010Mutually).

## Interactions
DLX2, a transcription factor, engages in several interactions with proteins and nucleic acids that influence its regulatory functions. One notable interaction is with the Evf-2 noncoding RNA (ncRNA), which is transcribed from the ultraconserved region between the Dlx-5 and Dlx-6 genes. Evf-2 forms a stable complex with DLX2 in vivo, enhancing the transcriptional activity of the Dlx-5/6 enhancer. This interaction is specific to DLX2, as Evf-2 does not form complexes with other proteins like Emx-1. The Evf-2/DLX2 complex stabilizes the interaction between DLX2 and target enhancer sequences, thereby enhancing transcriptional activity (Feng2006The).

DLX2 also interacts with the Lef-1 protein, a member of the lymphoid enhancer factor family. This interaction is crucial for the synergistic activation of the Msx2 promoter. DLX2 binds to the Msx2 promoter in vivo and can interact with multiple Lef-1 isoforms, including Lef-1 DN113, independent of the b-catenin binding domain. The CAD domain of Lef-1 is necessary for this synergistic activation, highlighting the importance of specific domains in their interaction (Diamond2006Functional).

Additionally, DLX2 can form heterodimeric complexes with Msx proteins, such as Msx1 and Msx2. These interactions are mediated through their homeodomains, which are necessary for DNA binding. However, the dimerization of Msx and Dlx proteins and their DNA binding are mutually exclusive, suggesting a functional antagonism where Msx proteins can repress DLX2's transcriptional activity (Zhang1997Heterodimerization).


## References


[1. (Liu2008The) Xudong Liu, Natalia Novosedlik, Ami Wang, Melissa L Hudson, Ira L Cohen, Albert E Chudley, Cynthia J Forster-Gibson, Suzanne M E Lewis, and Jeanette J A Holden. The dlx1and dlx2 genes and susceptibility to autism spectrum disorders. European Journal of Human Genetics, 17(2):228–235, August 2008. URL: http://dx.doi.org/10.1038/ejhg.2008.148, doi:10.1038/ejhg.2008.148. This article has 64 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2008.148)

[2. (Zhang1997Heterodimerization) Hailan Zhang, Gezhi Hu, Hongyu Wang, Peter Sciavolino, Nancy Iler, Michael M. Shen, and Cory Abate-Shen. Heterodimerization of msx and dlx homeoproteins results in functional antagonism. Molecular and Cellular Biology, 17(5):2920–2932, May 1997. URL: http://dx.doi.org/10.1128/mcb.17.5.2920, doi:10.1128/mcb.17.5.2920. This article has 351 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.17.5.2920)

[3. (Levi2022DLX) Giovanni Levi, Nicolas Narboux-Nême, and Martine Cohen-Solal. Dlx genes in the development and maintenance of the vertebrate skeleton: implications for human pathologies. Cells, 11(20):3277, October 2022. URL: http://dx.doi.org/10.3390/cells11203277, doi:10.3390/cells11203277. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells11203277)

[4. (Tan2021DLX) Yinfei Tan and Joseph R. Testa. Dlx genes: roles in development and cancer. Cancers, 13(12):3005, June 2021. URL: http://dx.doi.org/10.3390/cancers13123005, doi:10.3390/cancers13123005. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13123005)

[5. (Morini2010Mutually) Monica Morini, Simonetta Astigiano, Yorick Gitton, Laura Emionite, Valentina Mirisola, Giovanni Levi, and Ottavia Barbieri. Mutually exclusive expression of dlx2 and dlx5/6 is associated with the metastatic potential of the human breast cancer cell line mda-mb-231. BMC Cancer, November 2010. URL: http://dx.doi.org/10.1186/1471-2407-10-649, doi:10.1186/1471-2407-10-649. This article has 40 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2407-10-649)

[6. (Diamond2006Functional) Evan Diamond, Melanie Amen, Qiaoyan Hu, Herbert M. Espinoza, and Brad A. Amendt. Functional interactions between dlx2 and lymphoid enhancer factor regulate msx2. Nucleic Acids Research, 34(20):5951–5965, November 2006. URL: http://dx.doi.org/10.1093/nar/gkl689, doi:10.1093/nar/gkl689. This article has 24 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gkl689)

[7. (Feng2006The) Jianchi Feng, Chunming Bi, Brian S. Clark, Rina Mady, Palak Shah, and Jhumku D. Kohtz. The evf-2 noncoding rna is transcribed from the dlx-5/6 ultraconserved region and functions as a dlx-2 transcriptional coactivator. Genes &amp; Development, 20(11):1470–1484, May 2006. URL: http://dx.doi.org/10.1101/gad.1416106, doi:10.1101/gad.1416106. This article has 592 citations.](https://doi.org/10.1101/gad.1416106)